Press "Enter" to skip to content

GSK/Tesaro PARP inhibitor Zejula wins another speedy review – Endpoints News

admin 0

GSK/Tesaro PARP inhibitor Zejula wins another speedy review  Endpoints News

“The results of the QUADRA study demonstrate that ZEJULA is active as a late-line treatment for patients beyond those with BRCA mutations,” said Tesaro’s …

“liver cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *